Brickroad
Brickroad
IndexSignalsBlog

Product

  • Information Frontier Agent
  • Vendor Management Agent
  • Product tour
  • Pricing

Solutions

  • Utility estimation
  • Context assembly
  • Market intelligence

Suppliers

  • Sell your data
  • Start onboarding
  • Programmatic Data License

Community

  • Public index
  • Signals
  • Blog

Company

  • About
  • Team
  • Careers
  • Brand

Connect

  • LinkedIn
  • X
PrivacyTermsCookies

© 2026 Brickroad

/ Index / Approve Suite / Approve Suite

Approve Suite

Approve Suiteapprovesuite.com Health CareAlternativeSentimentUS

A continuously refreshed, machine-readable regulatory-event stream built over eight public U.S. sources (FDA warning letters, FDA inspection classifications, openFDA recalls, Federal Register, eCFR Title 21, ClinicalTrials.gov, Drugs@FDA approvals and complete response letters, SEC EDGAR 8-K disclosures), where each raw record is re-published as a normalised event carrying a written summary, a 'why it matters' explanation, the CFR sections cited, a GxP-area tag, a severity tier, and a resolved company/indication/product-type identity — plus company profiles that fuse the FDA record with trial and financial data.

Format
Multimodal
Are you Approve Suite?Manage this listing
OverviewSampleAt a glanceInventory and coverageSupplier
SampleSign in to see the sample, or to ask for one.Sign in

At a glance

From the index
Sector
Health Care
Data
AlternativeSentimentReference
Industry
BiotechnologyPharmaceuticalsResearch & Consulting Services
Themes
AlternativeSentimentReference
Instruments
Equities
Coverage
US
Procurement
HIGH — the operator already sells its data as a product, not just as a user interface: a metered API with per-key quotas is live, and its own developer documentation invites email contact specifically for 'redistribution, bulk snapshots or an OEM licence'. A buyer therefore negotiates with a willing, already-structured counterparty rather than educating one. Counterweight: the company publishes no named staff or partnerships role, so the counterparty is likely a very small team.

Inventory and coverage

Coverage

Equities in US. Related tickers MRNA, BNTX, VKTX, NTLA, CRSP, RLAY, IBIO.

Format

Multimodal, machine-first: typed JSON event records served over a bearer-token REST API with a published OpenAPI schema and an MCP endpoint, each record pairing structured fields (event type, severity, GxP area, modality, stage, company, CFR references) with generated prose summaries and links back to the source documents.

Volume

Eight source feeds ingested continuously — inspections and approvals refreshed daily, the rest every two to six hours — annotated one record at a time with a summary, a relevance explanation and CFR/GxP tags. FDA publishes warning letters in the low hundreds per year, inspection classifications in the thousands, recalls in the tens of thousands, Title 21 Federal Register items and section-level eCFR amendments in the thousands, trial registration and status changes in the tens of thousands, approvals and complete response letters in the hundreds, and matching 8-K disclosures in the low thousands — so the annotated archive is plausibly in the high hundreds of thousands of enriched event records at a few hundred tokens of generated annotation each.

Structure

Per-event severity classification (Critical / Important / FYI) assigned by the platform's own triage; mapping of every eCFR amendment to a GxP area and to the guidances that cite it; inspection outcome labels (NAI / VAI / OAI) with their citations by site; recall class and product-type labels; indication, modality and development-stage tags on trials; and cross-source company identity resolution tying an FDA inspection, a CRL and an EDGAR filer to one entity.

Supplier

Approve Suiteapprovesuite.com

Approve Suite — A continuously refreshed, machine-readable regulatory-event stream built over eight public U.S. sources (FDA warning letters, FDA inspection classifications, openFDA recalls, Federal Register, eCFR Title 21, ClinicalTrials.gov, Drugs@FDA approvals and complete response letters, SEC EDGAR 8-K disclosures), where each raw record is re-published as a normalised event carrying a written summary, a 'why it matters' explanation, the CFR sections cited, a GxP-area tag, a severity tier, and a resolved company/indication/product-type identity — plus company profiles that fuse the FDA r…

Supplier page

Not yet on file: Sample · Data dictionary · Data frequency · Reporting lag · Point-in-time · License

On this page
  • Overview
  • Sample
  • At a glance
  • Inventory and coverage
  • Supplier